Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 123-132

  Issekutz, Andrew C ^a   Rowter, Derek ^a   Miescher, Sylvia ^b   Käsermann, Fabian ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b CSL Behring   (Switzerland)

Author keywords

Cytokine; Immunomodulation; Lymphocyte; Proliferation; Sialyl IgG

Indexed keywords

CANDIDA ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SIALIC ACID; TRANSFORMING GROWTH FACTOR BETA; CD3 ANTIGEN; CYTOKINE; FUNGUS ANTIGEN; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; N ACETYLNEURAMINIC ACID;

ARTICLE; B LYMPHOCYTE; CANDIDA ALBICANS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIALYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; DRUG EFFECTS; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIGENS, CD3; ANTIGENS, FUNGAL; B-LYMPHOCYTES; CANDIDA ALBICANS; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IN VITRO TECHNIQUES; INFUSIONS, SUBCUTANEOUS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; N-ACETYLNEURAMINIC ACID; T-LYMPHOCYTES;

EID: 84938244540     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.05.003     Document Type: Article

References (48)

1. Bayry J., Dasgupta S., Misra N., Ephrem A., Duong Van Huyen J.P., Delignat S., Hassan G., Caligiuri G., Nicoletti A., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int. Immunopharmacol. 2006, 6:528-534.
2. Galeotti C., Bayry J., Kone-Paut I., Kaveri S.V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun. Rev. 2010, 9:441-448.
3. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 2012, 367:2015-2025.
4. Navarro R.P., Ballow M., Fenrick B., Pezalla E.J. Considerations for the optimal use of immunoglobulin. Am. J. Manage Care 2012, 18:S67-S78.
5. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
6. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
7. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011, 475:110-113.
8. Banda N.K., Wood A.K., Takahashi K., Levitt B., Rudd P.M., Royle L., Abrahams J.L., Stahl G.L., Holers V.M., Arend W.P. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008, 58:3081-3089.
9. Stadlmann J., Weber A., Pabst M., Anderle H., Kunert R., Ehrlich H.J., Peter Schwarz H., Altmann F. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009, 9:4143-4153.
10. Wuhrer M., Stam J.C., van de Geijn F.E., Koeleman C.A., Verrips C.T., Dolhain R.J., Hokke C.H., Deelder A.M. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 2007, 7:4070-4081.
11. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 2010, 30(Suppl. 1):S9-S14.
12. Crispin M., Yu X., Bowden T.A. Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E3544-E3546.
13. Yu X., Vasiljevic S., Mitchell D.A., Crispin M., Scanlan C.N. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J. Mol. Biol. 2013, 425:1253-1258.
14. Othy S., Topcu S., Saha C., Kothapalli P., Lacroix-Desmazes S., Kasermann F., Miescher S., Bayry J., Kaveri S.V. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur. J. Immunol. 2014, 44:2059-2063.
15. Campbell I.K., Miescher S., Branch D.R., Mott P.J., Lazarus A.H., Han D., Maraskovsky E., Zuercher A.W., Neschadim A., Leontyev D., McKenzie B.S., Kasermann F. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J. Immunol. 2014, 192:5031-5038.
16. Leontyev D., Katsman Y., Ma X.Z., Miescher S., Kasermann F., Branch D.R. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012, 52:1799-1805.
17. Durandy A., Kaveri S.V., Kuijpers T.W., Basta M., Miescher S., Ravetch J.V., Rieben R. Intravenous immunoglobulins - understanding properties and mechanisms. Clin. Exp. Immunol. 2009, 158(Suppl. 1):2-13.
18. Kwekkeboom J. Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies. Adv. Exp. Med. Biol. 2012, 750:133-144.
19. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 2013, 13:176-189.
20. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
21. Aubin E., Proulx D.P., Trepanier P., Lemieux R., Bazin R. Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation. Clin. Immunol. 2011, 141:273-283.
22. Kessel A., Ammuri H., Peri R., Pavlotzky E.R., Blank M., Shoenfeld Y., Toubi E. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 2007, 179:5571-5575.
23. Cousens L.P., Najafian N., Mingozzi F., Elyaman W., Mazer B., Moise L., Messitt T.J., Su Y., Sayegh M., High K., Khoury S.J., Scott D.W., De Groot A.S. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 2013, 33(Suppl. 1):S43-S49.
24. Maddur M.S., Othy S., Hegde P., Vani J., Lacroix-Desmazes S., Bayry J., Kaveri S.V. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J. Clin. Immunol. 2010, 30(Suppl. 1):S4-S8.
25. Ephrem A., Chamat S., Miquel C., Fisson S., Mouthon L., Caligiuri G., Delignat S., Elluru S., Bayry J., Lacroix-Desmazes S., Cohen J.L., Salomon B.L., Kazatchkine M.D., Kaveri S.V., Misra N. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
26. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun. Rev. 2011, 10:809-810.
27. Maddur M.S., Vani J., Hegde P., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 2011, 127:823-830. (e821-827).
28. Adelman M.K., Schluter S.F., Robey I.F., Marchalonis J.J. Natural and autoantibodies to human T-cell receptor Vbeta segments: potential roles in immunomodulation. Crit. Rev. Immunol. 2007, 27:221-232.
29. Bendtzen K., Svenson M., Hansen M. Autoantibodies to cytokines in IVIG. J. Rheumatol. 1993, 20:2176-2177.
30. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun. Rev. 2012, 11:792-794.
31. Schluter S.F., Adelman M.K., Taneja V., David C., Yocum D.E., Marchalonis J.J. Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation. Cell. Mol. Biol. 2003, 49:193-207.
32. Spath P.J., Lutz H.U. Naturally occurring antibodies/autoantibodies in polyclonal immunoglobulin concentrates. Adv. Exp. Med. Biol. 2012, 750:239-261.
33. Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayry J., Kaveri S.V. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun. Rev. 2008, 7:440-444.
34. von Gunten S., Simon H.U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 2008, 7:453-456.
35. MacMillan H.F., Lee T., Issekutz A.C. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin. Immunol. 2009, 132:222-233.
36. Shapiro R.S. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr. Allergy Immunol. 2013, 24:49-53.
37. Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann. Allergy Asthma Immunol. 2013, 111:S2-S5.
38. Kasermann F., Boerema D.J., Ruegsegger M., Hofmann A., Wymann S., Zuercher A.W., Miescher S. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012, 7:e37243.
39. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19571-19578.
40. Toyoda M., Pao A., Petrosian A., Jordan S.C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am. J. Transplant. 2003, 3:156-166.
41. Paquin Proulx D., Aubin E., Lemieux R., Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin. Immunol. 2010, 135:422-429.
42. Arend W.P., Leung D.Y. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol. Rev. 1994, 139:71-78.
43. Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C., Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994, 84:2136-2143.
44. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., Bleeker W.K. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
45. Schaub A., Wymann S., Heller M., Ghielmetti M., Beleznay Z., Stadler B.M., Bolli R., Miescher S. Self-reactivity in the dimeric intravenous immunoglobulin fraction. Ann. N. Y. Acad. Sci. 2007, 1110:681-693.
46. Miescher S.M., Schaub A., Ghielmetti M., Baumann M., Vogel M., Bolli R., Stadler B. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin. Ann. N. Y. Acad. Sci. 2005, 1051:582-590.
47. Tha-In T., Metselaar H.J., Tilanus H.W., Groothuismink Z.M., Kuipers E.J., de Man R.A., Kwekkeboom J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 2007, 110:3253-3262.
48. Miescher S.M., Kasermann F. The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease. Autoimmun. Rev. 2013, 12:639-642.